Interview: Novartis Counts On AS and PsA For Cosentyx Growth

Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.

Husky
Novartis looks to lead the pack in AS and PsA

Novartis AG has presented yet more data on Cosentyx (secukinumab) at the European League Against Rheumatism (EULAR) congress in Amsterdam which it believes will help the drug achieve a leading position in ankylosing spondylitis (AS) and psoriatic arthritis (PsA), as well as psoriasis.

In an interview with Scrip on the sidelines of EULAR, Eric Hughes, global development head of immunology, hepatology and dermatology,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category